Entero Therapeutics, Inc. announced a 1 for 3 reverse stock split of its common stock.
The reverse stock split was approved by the Board of Directors and shareholders to regain compliance with Nasdaq requirements.
After the reverse split, the outstanding common stock will be reduced from approximately 4.77 million shares to about 1.59 million shares.
Reverse Stock Split
Entero Therapeutics, Inc. is implementing a 1 for 3 reverse stock split to comply with Nasdaq listing rules.
Shareholder Impact
Shareholders will see a reduction in outstanding common stock shares after the split.
Nasdaq Compliance
The company aims to maintain its Nasdaq Capital Market listing through this reverse stock split.
- The visibility and credibility associated with a Nasdaq listing are crucial for the company's value and growth.
- The reverse stock split is a strategic move to enhance shareholder value and maintain market presence.
The reverse stock split is a necessary step for Entero Therapeutics, Inc. to uphold its Nasdaq listing and provide value to its shareholders.